PURE Bioscience, Inc.
PURE · OTC
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Market Cap | – | $10,045 | $6,723 | $8,054 |
| - Cash | $509 | $334 | $540 | $202 |
| + Debt | $3,573 | $5,236 | $4,899 | $3,975 |
| Enterprise Value | – | $14,947 | $11,082 | $11,827 |
| Revenue | $708 | $764 | $491 | $391 |
| % Growth | -7.3% | 55.6% | 25.6% | – |
| Gross Profit | $450 | $1,302,165 | $283 | $227 |
| % Margin | 63.6% | 170,440.4% | 57.6% | 58.1% |
| EBITDA | -$369 | -$243 | -$501 | -$727 |
| % Margin | -52.1% | -31.8% | -102% | -185.9% |
| Net Income | -$464 | -$332 | -$580 | -$798 |
| % Margin | -65.5% | -43.5% | -118.1% | -204.1% |
| EPS Diluted | -0.004 | -0.003 | -0.005 | -0.007 |
| % Growth | -36.7% | 42.3% | 26.8% | – |
| Operating Cash Flow | -$250 | -$456 | -$512 | -$544 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$250 | -$456 | -$512 | -$544 |